Caris Life Sciences Announces Participation in the 18th Annual Morgan Stanley Global Healthcare Conference

Caris Life Sciences 宣布参加摩根士丹利第18届全球医疗保健大会

2020-09-09 21:01:39 BioSpace

本文共1459个字,阅读需4分钟

Brian J. Brille to present a fireside chat covering molecular science and precision medicine Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced today that Brian J. Brille, Vice Chairman of the Company, will participate in a fireside chat at the 18th Annual Morgan Stanley Global Healthcare Conference Thursday, Sept. 17, 2020, at 9:30 a.m. Eastern time. Mr. Brille will provide an overview of Caris' business, along with its suite of market-leading molecular profiling offerings, and discuss recent corporate growth initiatives that position Caris to further extend its leadership reach in the market. Thomas Parker, Senior Vice President and Chief Financial Officer at Caris, will be available for Q&A. Attendees who would like to schedule a one-on-one meeting with Caris executives may do so by contacting their Morgan Stanley representative. About Caris Life Sciences Caris Life Sciences® is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation. The company's suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps physicians and cancer patients make more precise and personalized treatment decisions. MI Exome™ whole exome sequencing with 22,000 DNA genes, and MI Transcriptome™ whole transcriptome sequencing with 22,000 RNA genes along with cancer-related pathogens, bacteria, viruses and fungi analysis run on every patient provides the most comprehensive and clinically relevant DNA and RNA profiling available on the market. Caris is also advancing precision medicine with Caris MAI™ (Molecular Artificial Intelligence) that combines its innovative service offerings, Caris Molecular Intelligence® with its proprietary artificial intelligence analytics engine, DEAN™, to analyze the whole exome, whole transcriptome and complete cancer proteome. This information, coupled with mature clinical outcomes on thousands of patients, provides unmatched molecular solutions for patients, physicians, payers and biopharmaceutical organizations. Caris Pharmatech is changing the paradigm and streamlines the clinical trial process by assisting biopharma companies with accessing research-ready oncology sites for clinical trials. With over 200 research sites within the Caris Pharmatech JIT Oncology Network, biopharma companies can identify and enroll more patients, faster. Caris Pharmatech Just-In-Time Clinical Trial Solutions focus on rapid site activation and patient enrollment to streamline the drug development process. By implementing a Just-In-Time (JIT) Research System, site activation and patient enrollment is achievable within 14 days for pre-registered locations with pre-qualified patients. Headquartered in Irving, Texas, Caris Life Sciences has offices in Phoenix, Denver, New York, and Basel, Switzerland. Caris provides services throughout the U.S., Europe, Asia and other international markets. To learn more, please visit www.CarisLifeSciences.com or follow us on Twitter (@CarisLS). Investor Inquiries: Argot Partners caris@argotpartners.com 212-600-1902 Media Contact: Lindsey Bailys GCI Health lindsey.bailys@gcihealth.com 212-798-9884 multimedia:http://www.prnewswire.com/news-releases/caris-life-sciences-announces-participation-in-the-18th-annual-morgan-stanley-global-healthcare-conference-301126136.html
Brian J . Brille 介绍了关于分子科学和精密医学的炉边聊天 致力于实现精准医疗的分子科学领域的领先创新者 Caris Life Sciences ®今天宣布,公司副董事长 Brian J . Brille 将于2020年9月17日(星期四)东部时间上午9:30参加第18届摩根士丹利全球医疗保健年会的炉边讨论。 Brille 先生将概述 Caris 的业务及其一系列市场领先的分子分析产品,并讨论近期的公司增长举措,使 Caris 能够进一步扩大其在市场上的领导地位。Caris 高级副总裁兼首席财务官 Thomas Parker 将提供 Q & A 。 希望与 Caris 高管安排一对一会议的与会者可以联系他们的摩根士丹利代表。 关于 Caris 生命科学 Caris Life Sciences ®是分子科学领域的领先创新者,致力于通过质量和创新实现精准医疗的承诺。该公司的一系列市场领先的分子分析产品评估 DNA 、 RNA 和蛋白质,以揭示分子蓝图,帮助医生和癌症患者做出更精确和个性化的治疗决策。对每个患者进行22,000个 DNA 基因的 MI exome ™全外显子测序和22,000个 RNA 基因的 MI Transcriptme ™全转录序列以及与癌症相关的病原体、细菌、病毒和真菌分析,可提供市场上最全面和临床相关的 DNA 和 RNA 图谱。 Caris 还与 Caris MAI ™( Molecular AI AI ™)合作推进精准医疗,后者将其创新的服务产品 Caris Molecular Intelligence ®与其专有的人工智能分析引擎 DEA ™结合起来,分析整个外显子、完整的成绩单和完整的癌症蛋白组。这些信息,加上数千名患者的成熟临床结果,为患者、医生、付款人和生物制药组织提供了无与伦比的分子解决方案。 Caris Phamatech 正在改变这种模式,并通过帮助生物制药公司进入研究准备好的肿瘤临床试验场所,简化临床试验过程。在 Caris Pharmathech JIT 肿瘤网络内有200多个研究站点,生物制药公司可以更快地识别和招募更多的患者。Caris Pharmathech Just-In-Time Clinical 试用解决方案专注于快速现场激活和患者注册,以简化药物开发过程。通过实施准时制( JIT )研究系统,可以在14天内对预先注册的有资格的患者的地点进行现场激活和患者登记。 Caris 生命科学公司总部位于德克萨斯州的欧文,在凤凰城、丹佛、纽约和瑞士巴塞尔设有办事处。Caris 在美国、欧洲、亚洲和其他国际市场提供服务。要了解更多信息,请访问 www.CarisLifeSciences.com 或在 Twitter (@ CarisLS )上关注我们。 投资者询价情况: Argot Partners caris @ argotpartners.com 212-600-1902 媒体联系人: 林赛·贝利 GCI 健康 lindsey 。bellys @ gchiealth.com 212-798-9884 多媒体: http://www.prnewswire.com/news-releases/caris-life-sciences-annound-join-18-annual-morgan-stanley-global-health-meeting-meeting-conference-3011163。html

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文